We reviewed randomized phase II/III trials comparing first-or second-line endocrine therapy as monotherapy or in combination with targeted therapies for treatment of postmenopausal patients with hormone receptor-positive advanced breast cancer. First-line was defined as treatment for endocrine therapy-naïve advanced breast cancer or advanced disease treated with endocrine therapy in the adjuvant/neoadjuvant setting. Second-line was defined as endocrine therapy for advanced breast cancer following disease progression on endocrine therapy for advanced disease. Publications reporting progression-free survival (PFS)/time to progression (TTP) or overall survival (OS) for FDA-approved agents anastrozole, exemestane, fulvestrant 250 mg, fulvestrant 500 mg, letrozole (0.5 and 2.5 mg), megestrol acetate, and tamoxifen as monotherapy, or in combination with everolimus, palbociclib or ribociclib, were assessed. First-line monotherapy with anastrozole, fulvestrant 500 mg or letrozole 2.5 mg significantly improved PFS/TTP versus comparator endocrine therapy; however, only fulvestrant 500 mg improved OS. For endocrine therapy in combination with targeted therapies, palbociclib plus letrozole 2.5 mg, and ribociclib plus letrozole 2.5 mg significantly improved PFS versus letrozole 2.5 mg alone first-line. For second-line monotherapies, exemestane, fulvestrant 500 mg and letrozole 2.5 mg significantly improved PFS/TTP versus comparator endocrine therapy; only fulvestrant 500 mg and letrozole 2.5 mg improved OS. For second-line combination therapies, everolimus plus exemestane, and palbociclib plus fulvestrant 500 mg, improved PFS versus endocrine therapy alone. In both first-and second-line settings, aromatase inhibitors demonstrated PFS benefits versus comparator endocrine therapy; however, fulvestrant 500 mg was the only endocrine therapy included in our review to show both PFS and OS advantages compared with other endocrine therapies. Targeted agents in combination with endocrine therapy have demonstrated PFS improvements both first-and second-line; OS data are awaited.
Introduction
Approximately 250,000 new cases of breast cancer are diagnosed each year, 1 and over two-thirds of these patients will be categorized as having hormone receptor-positive disease. 2 For patients with hormone receptor-positive advanced breast cancer, clinical guidelines recommend sequential treatment with endocrine therapy, unless they are experiencing visceral crises and/or endocrine resistance is known or suspected. [3] [4] [5] In addition, the targeted therapies everolimus, an allosteric inhibitor of mammalian target of rapamycin (mTOR), 6 and most recently palbociclib, a cyclin-dependent kinase 4/6 (CDK 4/6) inhibitor, 7, 8 have been approved for use in combination with endocrine therapies in either the first-or second-line setting. 9, 10 In addition, the CDK 4/6 inhibitor ribociclib, in combination with letrozole, has recently received FDA Breakthrough Therapy designation for the first-line treatment of hormone receptor-positive, human epidermal growth factor receptor 2-(HER2-) negative advanced or metastatic breast cancer. 11 In order for these agents to gain approval for treatment, regulatory authorities have required robust evidence of efficacy using endpoints including progression-free survival (PFS)/time to progression (TTP) and overall survival (OS), each of which is subject to some limitations. OS is considered to be a more objective measure than other outcomes, 12 but requires large patient cohorts and extensive follow-up times. OS may also be influenced by subsequent post-trial therapies, particularly in settings such as breast cancer where many effective treatments are available, and could be confounded by deaths not attributable to cancer.
PFS/TTP values are derived from tumor-based assessments, and can be obtained in a shorter time frame than OS; therefore, these outcome measures may be more suited to accelerated approval schemes. Moreover, these measures are not influenced by post-trial therapies, unlike OS. However, there is a potential for bias, particularly if treatment is not blinded. 12 In an ideal scenario, PFS/TTP may be regarded as a surrogate for OS; however, evidence suggests that these measures can diverge and are only moderately correlated. 13 In light of the recent approval of new therapies for the treatment of hormone receptor-positive advanced breast cancer, and the lack of direct comparisons between these agents, the aim of this review is to evaluate efficacy outcomes data, in terms of both published TTP/PFS and OS, from randomized clinical trials of endocrine therapy for hormone receptor-positive advanced breast cancer in both the first-and second-line settings.
Methods
A literature review was conducted using the MEDLINE database in order to identify randomized, controlled phase II or phase III trials that compared endocrine therapies as monotherapies or in combination with targeted therapies in the first-or second-line treatment of postmenopausal patients with hormone receptor-positive advanced breast cancer. For the purposes of this analysis, first-line treatment was defined as first endocrine therapy for advanced breast cancer. In this context, patients may have received prior adjuvant endocrine therapy for early disease. Second-line treatment was defined as endocrine therapy for advanced breast cancer following disease progression on endocrine therapy for advanced disease.
The search strategy included terms applicable to the patient population (postmenopausal women with locally advanced or metastatic breast cancer) and any publications identified during the literature review that reported TTP/PFS or OS data for the following endocrine monotherapies were eligible for further assessment: anastrozole 1 mg, exemestane 25 mg, fulvestrant 250 mg, fulvestrant 500 mg, letrozole 0.5 mg, letrozole 2.5 mg, megestrol acetate 160 mg, and tamoxifen 20 mg. Data for endocrine therapy in combination with available targeted therapies everolimus 10 mg and palbociclib 125 mg, which have been recently approved, and ribociclib 600 mg, were also included. Data were evaluated from publications reporting either the primary or follow-up analyses. Only English-language publications were reviewed and no date restrictions were applied. No congress abstracts were reviewed. Studies that focused on hormone receptor-positive, HER2-positive disease and publications presenting data for combinations of endocrine therapies with novel treatments, such as inhibitors of HER-2, histone deacetylase (HDAC), insulin-like growth factor receptor (IGFR) and phosphatidyl-inositol 3-kinase (PI3K), were not included. Studies with HER2 unknown or HER2-negative status were included.
For each relevant publication identified, OS and TTP/PFS, median duration of treatment and/or follow up, and details of prior therapies or responsiveness to prior therapies are presented. For the purpose of this review, statistical significance was attributed according to the level of significance described in each study. 
Results

First-line treatment
Second-line treatment
In total, 14 studies were identified that reported PFS/TTP with endocrine therapy alone in the second-line setting (Table 2) ; of these, three and seven studies reported results of phase II and III trials, respectively (phase not disclosed for three studies).
The ranges of PFS/TTP reported were 3. In the phase II TAMRAD study, the combination of tamoxifen and everolimus was compared with tamoxifen alone and demonstrated an improvement in TTP (HR 0.54, 95% CI 0.36-0.81; p = 0.0021). 45 In the phase III BOLERO-2 study, the addition of everolimus to exemestane significantly increased PFS compared with exemestane alone (HR 0.45; 95% CI 0.38-0.54; p < 0.0001). 32 Palbociclib in combination with fulvestrant 500 mg significantly improved PFS versus fulvestrant 500 mg alone (HR 0.46; 95% CI 0.36-0.59; p < 0.0001) in the phase III PALOMA-3 study. 7, 8 OS with second-line endocrine monotherapy ranged from 26.7 to 27.7 months with anastrozole (from two studies); 30 30 and exemestane versus megestrol acetate (p = 0.039) in one study. 31 In the small phase II TAMRAD trial, the combination of everolimus and tamoxifen suggested an improvement in OS for the combination compared with tamoxifen alone (HR 0.45; 95% CI 0.24-0.81; p = 0.007). 45 However, in the much larger phase III BOLERO-2 trial, the addition of everolimus to exemestane therapy did not significantly increase OS compared with exemestane alone (HR 0.89; 95% CI 0.73-1.10; p = 0.14). 33 OS data for the combination of palbociclib with fulvestrant was not mature at the time of publication of the final analysis results. 7
Discussion
We conducted a comprehensive literature review with the objective of providing an overview of efficacy in terms of TTP/PFS and OS findings from randomized controlled studies evaluating approved endocrine therapies (as monotherapy and in combination with targeted therapies) for the first-and second-line treatment of postmenopausal women with hormone receptor-positive advanced breast cancer. As the objective of this review was to evaluate the PFS and OS data for approved endocrine therapies, we do not review quality of life, toxicity, cost, definitions of endocrine resistance or analyses of biomarkers.
In the first-line setting, anastrozole, fulvestrant 500 mg and letrozole 2.5 mg were reported to significantly improve PFS/TTP versus a comparator endocrine therapy. 21, 24, 25, 29 In this setting, fulvestrant 500 mg also provided a significant OS advantage compared with anastrozole in a phase II study, although the analysis of OS was not prespecified. 23 Concerning first-line targeted therapies, palbociclib in combination with letrozole 2.5 mg (PALOMA-1 study) significantly improved PFS compared with letrozole 2.5 mg alone; however, OS data were not significantly different between treatment arms and this phase II study was not powered to demonstrate OS benefit. 27 In the phase III PALOMA-2 study, PFS improvement was demonstrated for the combination of palbociclib and letrozole 2.5 mg versus letrozole 2.5 mg alone. Data were not sufficiently mature to allow an analysis of OS (this will be the subject of a follow-up analysis). 28 In a recently published phase III study, a significant improvement in PFS with ribociclib in combination with letrozole 2.5 mg compared with letrozole 2.5 mg alone was reported; 11 however, OS data from this study were not mature at the time of the interim analysis.
Exemestane, fulvestrant 500 mg, anastrozole and letrozole 2.5 mg as second-line treatment of hormone receptor-positive advanced breast cancer were reported to significantly improve PFS/TTP over a comparator endocrine therapy. 31, 39, 43, 44 Subsequent significant OS advantages versus comparators were observed for fulvestrant 500 mg, anastrozole and letrozole 2.5 mg, and exemestane. 30, 31, 40, 43, 44 Of note, fulvestrant 500 mg and letrozole 2.5 mg demonstrated OS advantages compared with fulvestrant 250 mg and letrozole 0.5 mg, respectively. 40, 43, 44 The mTOR inhibitor everolimus in combination with tamoxifen improved TTP and OS versus tamoxifen alone in the small phase II TAMRAD trial. 45 The combination of everolimus with exemestane in the phase III BOLERO-2 study improved PFS versus exemestane as a single agent; 32 however, this finding did not translate into improved OS, 33 although it must be noted that this study was powered to detect statistical significance with an 8-month improvement in OS. Results of the phase III PALOMA-3 study demonstrated that palbociclib in combination with fulvestrant 500 mg significantly improved PFS compared with fulvestrant 500 mg alone. 7, 8 OS data from this study are pending and are awaited with interest.
Fulvestrant 500 mg is the only endocrine therapy of those included in our review that showed improvements in both PFS/TTP and OS in both the first-and second-line treatment of postmenopausal women with hormone receptor-positive advanced breast cancer compared with other endocrine therapies. Fulvestrant 500 mg was associated with improved OS versus anastrozole in the phase II FIRST study (54.1 versus 48.4 months, respectively). However, this finding should be interpreted with caution, given the limitations of the OS analysis in this study, which only included a small number of patients. 23 Confirmation of the significant improvement in PFS seen in the phase II FIRST study with fulvestrant over anastrozole was demonstrated in the recently published phase III FALCON study. 24 Furthermore, results of a post hoc analysis of data in the FALCON study demonstrated that the improvement in PFS with fulvestrant versus anastrozole was greater in patients with non-visceral disease compared with patients with visceral disease; however, further studies are required to confirm this finding. Of note, patients in this study had not received any prior endocrine therapy, a patient population for which there is a paucity of data, 46 which limits the generalizability of the findings.
Our analysis included an evaluation of studies reporting the comparative efficacy of endocrine therapies as monotherapy. However, it should be noted that few studies have investigated the efficacy of combinations of endocrine therapies versus endocrine therapy alone. 47 To our knowledge, no significant differences in efficacy have been reported with endocrine therapy combinations over monotherapy, 48, 49 with the exception of one study that demonstrated significant improvement in PFS for a combination of anastrozole and fulvestrant versus anastrozole alone. 50 Consequently, no definitive changes to clinical practice based on these findings have occurred.
Furthermore, in order to optimize treatment for individual patients, it is important to consider the impact of treatment on several factors in addition to efficacy, including quality of life, treatmentrelated adverse events and cost; however, a review of these aspects is beyond the scope of this article.
Key limitations of our data set include the substantial heterogeneity in the patient populations and the paucity of available information describing patients' prior exposure to endocrine therapy, number of previous treatments (chemotherapy and endocrine therapy) and duration of response to prior therapy, which make cross-trial comparisons difficult.
In this review, first-line treatment has been uniformly defined as first endocrine therapy for advanced breast cancer; however, prior adjuvant endocrine treatment was allowed in many studies. Therefore this does not represent first exposure to endocrine treatment, and may have biologic consequences that are not appropriately addressed in these studies. Prior exposure to endocrine therapy may therefore be a more precise parameter by which studies could be classified; 47 however, given the limitations described above, this would be difficult to ascertain for all studies included in this analysis.
It should be highlighted that the patient populations included in these trials would be expected to include a subpopulation of patients with hormone receptor-positive and HER2-positive advanced or metastatic breast cancer; however, few studies reported these data. According to the most recent guidelines, treatment recommendations for these patients include anti-HER2 therapy in combination with chemotherapy or endocrine therapy, 51 thus the presence of this cohort in the studies may have a confounding, albeit small, effect. For this reason, studies excluding these patients may provide a more representative population in which to evaluate the efficacy of endocrine therapies.
In addition, this literature review confined its evaluation to the efficacy of endocrine treatment in postmenopausal women only, with the exception of the PALOMA-3 trial, which also included premenopausal and perimenopausal patients who were rendered postmenopausal through administration of a gonadotropin-releasing hormone (GnRH) agonist goserelin for the duration of the study. 7, 8 Treatment recommendations suggest that premenopausal women with advanced breast cancer should follow the same treatment algorithm as postmenopausal women with additional ovarian suppression; 51 however, there is underrepresentation of premenopausal women in clinical trials, and inclusion of this patient population in future trial designs would benefit clinical practice. To date, data on the use of endocrine therapy as a treatment for premenopausal women with advanced breast cancer are limited; however, the results of the PALOMA-3 trial suggested similar PFS with palbociclib plus fulvestrant in these patient subgroups compared with postmenopausal women. 7, 8 Moreover, the results of the phase III, randomized MONALEESA-7 study [ClinicalTrials.gov identifier: NCT02278120] of ribociclib or placebo plus tamoxifen and goserelin or an aromatase inhibitor in premenopausal women are eagerly awaited.
An important conclusion to be drawn from the available evidence base is that fulvestrant is currently the best available single-agent endocrine therapy, as demonstrated in the FALCON trial. 24 It is expected that fulvestrant will form the backbone of future combination strategies attempting to modulate endocrine resistance. The results of the ongoing phase II randomized, open-label PARSIFAL study [ClinicalTrials.gov identifier: NCT02491983] of palbociclib combined with fulvestrant or letrozole in advanced breast cancer, once available, will help to inform these strategies. It should be acknowledged that regardless of the findings of this analysis and despite OS data not being available, the addition of a CDK 4/6 inhibitor to an aromatase inhibitor is often selected as a preferred treatment choice based on the improvements in PFS seen with these combinations.
With the increasing number of alternative options for treating hormone receptor-positive advanced breast cancer, one critical aspect that warrants further investigation is how best to sequence each of the available therapies. Unfortunately, we have been unable to perform trials addressing this particular and very important issue. As patients derive additional benefits from current treatments and are able to receive more lines of therapy after an initial progression, it remains a significant challenge to demonstrate OS benefits in this scenario. This issue should be considered in the design and interpretation of future trials and in the regulatory criteria for drug approval.
In conclusion, our literature review reports on the use of endocrine therapy as first-and second-line treatment of postmenopausal women with hormone receptor-positive advanced or metastatic breast cancer. Patient selection strategies, development of predictive biomarkers, longer time frame follow-up information from reported studies, adequate data on lines of therapy after progression and the results of ongoing large randomized studies will add to the evidence base in this therapy area.
